Charles River Laboratories Intl. Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $303.44 (market cap $14.23B), while Vanguard Total Stock Market Index Fund ETF trades at $382.14 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 161.6× Charles River Laboratories Intl. Inc's market cap, and Vanguard Total Stock Market Index Fund ETF is more actively traded (2,982,924 versus 1,176,885). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Vanguard Total Stock Market Index Fund ETF for 131 Days on average.
| CRL | VTI | |
|---|---|---|
Market Cap | $14.23B | $2.30T |
Volume | 1,176,885 | 2,982,924 |
Sector | Health | — |
52-Week High | $310.77 | $384.30 |
52-Week Low | $149.93 | $311.68 |
Typical Hold Time | 33 Days | 131 Days |
Enterprise Value | $17.06B | — |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
VTI trades at $381.82, up 0.21% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF shows strong institutional interest and broad diversification across the U.S. stock market. Recent news highlights its long-term growth potential and cost efficiency, with a dividend scheduled for September 2026.
The outlook for VTI remains positive due to its low-cost structure and exposure to the entire U.S. equity market. Risks include concentration in top holdings and market volatility, but its historical performance supports a solid foundation for long-term investors seeking diversified growth.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →